Real-World Prevalence Of Programmed Death Ligand 1 Expression In Locally Advanced Or Metastatic Non Small-Cell Lung Cancer: The Global, Multicenter Express Study

Objectives: : Tumor programmed death ligand 1 (PD-L1) expression is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with NSCLC.Materials and methods: : Patients >= 18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (<= 5 years old) obtained before treatment were identified in 45 centers across 18 countries. Tumor samples from eligible patients were selected consecutively, when possible. PD-L1 expression was evaluated at each center using the PD-L1 IHC 22C3 pharmDx kit (Agilent, Santa Clara, CA, USA).Results: : Of 2617 patients who met inclusion criteria, 2368 (90%) had PD-L1 data; 530 (22%) patients had PD-L1 TPS >= 50%, 1232 (52%) had PD-L1 TPS >= 1%, and 1136 (48 %) had PD-L1 TPS < 1%. The most common reason for not having PD-L1 data (n = 249) was insufficient tumor cells (< 100) on the slide (n = 170 [6%]). Percentages of patients with PD-L1 TPS >= 50% and TPS >= 1%, respectively were: 22%/52% in Europe; 22%/53% in Asia Pacific; 21%/47% in the Americas, and 24%/55% in other countries. Prevalence of EGFR mutations (19%) and ALK alterations (3%) was consistent with prior reports from metastatic NSCLC studies. Among 1064 patients negative for both EGER mutation and ALK alteration, the percentage with PD-L1 TPS >= 50% and TPS >= 1%, respectively, were 27% and 53%.Conclusions: : This is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit. Testing failure rate was low with local evaluation of PD-L1 TPS across a large number of centers. Prevalence of PD-L1 TPS >= 50% and TPS >= 1% among patients with stage IIIB/IV NSCLC was similar across geographic regions and broadly consistent with central testing results from clinical trial screening populations.